Is the price fair?
What PVLA's price assumes
Palvella Therapeutics, Inc. has no trailing P/E on file, so the price is measured against sales instead: 560× revenue.
560
Price / sales · no trailing P/E on file: measured against sales instead
- Price / book
- 7.02
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 7.02
- Market capitalisation
- $1.95B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.